Janssen Search
Search results
On the Road to Victories: Janssen Employees Cycle for Multiple Myeloma
On the Road to Victories: Janssen Employees Cycle for Multiple Myeloma Outpacing Cancer One Mile at a Time Raising money and awareness for a disease like multiple myeloma is an ambitious goal. Jamie, a California native living with multiple myeloma, knows ...
Our Stories
Stories Pull Quote: We're creating a future where disease is a thing of the past. With a deep responsibility to the people we serve, we work tirelessly to advance and improve how medicines are discovered, developed and made. Our Stories ...
Dirk Gevers, Ph.D.
DIRK GEVERS, PH.D. GLOBAL HEAD, MICROBIOME SOLUTIONS WORLD WITHOUT DISEASE ACCELERATOR As Global Head, Microbiome Solutions, World Without Disease Accelerator (WWDA), Dirk strengthens Janssen and Johnson & Johnson leadership, scientific understanding ...
Oncology Leadership Team
Leaders in Oncology “Our world-class oncology team is relentlessly focused on the discovery and development of treatments that will lead to cures for patients throughout the world.” Peter Lebowitz, M.D., Ph.D. Global Therapeutic Area Head, Oncology -- ...
JHMI included in White House Microbiome Initiative
JHMI included in White House Microbiome Initiative Jan 06, 2017 Article Type: Human Microbiome Institute Redirect URL: https://www.jnj.com/health-and-wellness/the-white-house-announces-new-funding-for-microbiome-research ...
Our Commitment to Rheumatology
Our Commitment to Rheumatology Jul 03, 2023 Subhead: Lorem ipsum dolor sit amet, consectetuer adipiscing elit About Rheumatoid Arthritis Rheumatoid arthritis (RA) is a chronic, symmetric, inflammatory disease involving the synovial joints, where bone and ...
Kurtis (Kurt) Bachman, Ph.D.
KURTIS (KURT) BACHMAN, PH.D. HEAD, COLORECTAL CANCER INTERCEPTION JANSSEN ONCOLOGY As Head of the Colorectal Cancer Interception team within Janssen Oncology, Kurt leads a team focused on intercepting the initiation and progression of colorectal cancer ...
RYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Mar 01, 2024 United States Approval is based on results from the Phase 3 PAPILLON study, which demonstrated RYBREVANT ® plus chemotherapy reduced the risk of disease progression or death by 61 percent versus chemotherapy alone in patients with previously ...
RYBREVANT® (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer
Sep 14, 2024 Spain Post-progression outcomes showed significant and sustained improvement for RYBREVANT ® plus standard of care versus chemotherapy alone BARCELONA, September 14, 2024 – Johnson & Johnson (NYSE:JNJ) today announced updated results from ...
Behavioral Neurobiology
Behavioral Neurobiology The Behavioral Neurobiology group is focused on executing foundational biological research into critical human behaviors known to impact the pathology of select diseases, to ultimately enable pharmaceutical or behavioral solutions ...